Surmodics, Inc. (SRDX): Price and Financial Metrics

Surmodics, Inc. (SRDX): $34.89

0.84 (+2.47%)

POWR Rating

Component Grades








SRDX Price/Volume Stats

Current price $34.89 52-week high $39.41
Prev. close $34.05 52-week low $16.00
Day low $34.37 Volume 13,642
Day high $35.21 Avg. volume 107,222
50-day MA $31.59 Dividend yield N/A
200-day MA $28.02 Market Cap 493.90M

SRDX Stock Price Chart Interactive Chart >


  • Sentiment is the dimension where SRDX ranks best; there it ranks ahead of 97.65% of US stocks.
  • The strongest trend for SRDX is in Growth, which has been heading up over the past 177 days.
  • SRDX's current lowest rank is in the Momentum metric (where it is better than 28.33% of US stocks).

SRDX Stock Summary

  • Price to trailing twelve month operating cash flow for SRDX is currently 44.96, higher than 92.29% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 194.05%, SURMODICS INC's debt growth rate surpasses 95.21% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, SURMODICS INC is reporting a growth rate of -127.29%; that's higher than just 10.72% of US stocks.
  • Stocks that are quantitatively similar to SRDX, based on their financial statements, market capitalization, and price volatility, are SONO, ALTR, FORM, INFN, and CWAN.
  • Visit SRDX's SEC page to see the company's official filings. To visit the company's web site, go to

SRDX Valuation Summary

  • In comparison to the median Healthcare stock, SRDX's EV/EBIT ratio is 2875.59% higher, now standing at 377.9.
  • SRDX's price/sales ratio has moved down 5.4 over the prior 243 months.

Below are key valuation metrics over time for SRDX.

Stock Date P/S P/B P/E EV/EBIT
SRDX 2023-11-20 3.8 4.4 -21.5 377.9
SRDX 2023-11-17 3.8 4.4 -21.6 379.8
SRDX 2023-11-16 3.7 4.3 -21.0 367.9
SRDX 2023-11-15 3.7 4.3 -20.8 365.6
SRDX 2023-11-14 3.7 4.4 -21.3 374.7
SRDX 2023-11-13 3.5 4.1 -19.9 349.3

SRDX Growth Metrics

    Its 5 year revenue growth rate is now at 37.07%.
  • Its 2 year revenue growth rate is now at -3.62%.
  • Its 5 year net cashflow from operations growth rate is now at -33.79%.
Over the past 34 months, SRDX's revenue has gone up $1,283,000.

The table below shows SRDX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 101.881 -20.999 -32.305
2022-09-30 99.951 -17.223 -27.274
2022-06-30 97.934 -13.834 -12.835
2022-03-31 96.953 -7.582 -10.471
2021-12-31 105.842 12.633 1.699
2021-09-30 105.136 15.389 4.237

SRDX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRDX has a Quality Grade of B, ranking ahead of 94.57% of graded US stocks.
  • SRDX's asset turnover comes in at 0.604 -- ranking 71st of 186 Medical Equipment stocks.
  • MMSI, POAI, and OSUR are the stocks whose asset turnover ratios are most correlated with SRDX.

The table below shows SRDX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.604 0.837 0.071
2021-03-31 0.632 0.848 0.115
2020-12-31 0.578 0.832 -0.017
2020-09-30 0.588 0.839 -0.016
2020-06-30 0.648 0.854 0.060
2020-03-31 0.648 0.861 0.063

SRDX Price Target

For more insight on analysts targets of SRDX, see our SRDX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $76.25 Average Broker Recommendation 1.25 (Strong Buy)

Surmodics, Inc. (SRDX) Company Bio

SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.

SRDX Latest News Stream

Event/Time News Detail
Loading, please wait...

SRDX Latest Social Stream

Loading social stream, please wait...

View Full SRDX Social Stream

Latest SRDX News From Around the Web

Below are the latest news stories about SURMODICS INC that investors may wish to consider to help them evaluate SRDX as an investment opportunity.

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

EDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 36-month data from its TRANSCEND clinical trial was presented by Dr. Peter A. Schneider at the 50th Annual VEITH Symposium in New York, New York.

Yahoo | November 16, 2023

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

EDEN PRAIRIE, Minn., November 16, 2023--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that 24-month data from the SWING Trial, a first-in-human study of the safety and performance of the Sundance™ Sirolimus Drug-Coated Balloon (DCB) was presented at the 50th annual VEITH Symposium in New York, New York.

Yahoo | November 16, 2023

Surmodics, Inc.'s (NASDAQ:SRDX) Intrinsic Value Is Potentially 91% Above Its Share Price

Key Insights Using the 2 Stage Free Cash Flow to Equity, Surmodics fair value estimate is US$66.09 Surmodics' US$34.64...

Yahoo | November 15, 2023

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

EDEN PRAIRIE, Minn., November 14, 2023--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the 35th Annual Piper Sandler Healthcare Conference, which is being held at the Lotte New York Palace in New York, NY from November 28-30, 2023. Management will present on Tuesday, November 28, at 8:30 a.m. ET (7:30 a.m. CT).

Yahoo | November 14, 2023

Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call Transcript

Surmodics, Inc. (NASDAQ:SRDX) Q4 2023 Earnings Call Transcript November 10, 2023 Operator: Welcome everyone to Surmodics Fourth Quarter and Fiscal Year 2023 Earnings Call. Please note that this call is being webcast. The webcast is accessible through the Investor Relations section of the Surmodics website at, where an audio replay will be archived for […]

Yahoo | November 11, 2023

Read More 'SRDX' Stories Here

SRDX Price Returns

1-mo 14.54%
3-mo -7.63%
6-mo 55.90%
1-year -2.43%
3-year -13.87%
5-year -38.96%
YTD 2.26%
2022 -29.14%
2021 10.64%
2020 5.04%
2019 -12.34%
2018 68.79%

Continue Researching SRDX

Here are a few links from around the web to help you further your research on Surmodics Inc's stock as an investment opportunity:

Surmodics Inc (SRDX) Stock Price | Nasdaq
Surmodics Inc (SRDX) Stock Quote, History and News - Yahoo Finance
Surmodics Inc (SRDX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!